GKOS:NYE-Glaukos Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 151.16

Change

0.00 (0.00)%

Market Cap

USD 1.10B

Volume

0.54M

Analyst Target

USD 48.89
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-28 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

N/A

USD 200.50B
MDT Medtronic PLC

N/A

USD 103.90B
ZBH Zimmer Biomet Holdings Inc

N/A

USD 21.28B
STE STERIS plc

N/A

USD 20.53B
GMED Globus Medical

N/A

USD 11.25B
SNN Smith & Nephew SNATS Inc

N/A

USD 10.75B
PEN Penumbra Inc

N/A

USD 9.31B
BIO Bio-Rad Laboratories Inc

N/A

USD 9.17B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.16B
INSP Inspire Medical Systems Inc

N/A

USD 5.63B

ETFs Containing GKOS

PSCH Invesco S&P SmallCap Heal.. 5.37 % 0.29 %

N/A

USD 0.18B
XHE SPDR® S&P Health Care Eq.. 2.12 % 0.35 %

N/A

USD 0.21B
VIOG Vanguard S&P Small-Cap 60.. 1.05 % 0.20 %

N/A

USD 1.02B
MWON:XETRA Amundi S&P SmallCap 600 E.. 0.89 % 0.00 %

N/A

USD 0.42B
USASUS:SW Amundi S&P SmallCap 600 E.. 0.89 % 0.00 %

N/A

USD 0.42B
ESIX SPDR S&P SmallCap 600 ESG.. 0.83 % 0.00 %

N/A

USD 7.58M
CBUSAS:SW Amundi S&P SmallCap 600 E.. 0.75 % 0.00 %

N/A

N/A
ISP6:LSE iShares III Public Limite.. 0.60 % 0.00 %

N/A

USD 3.04B
IDP6:SW iShares S&P SmallCap 600 .. 0.53 % 0.00 %

N/A

USD 3.04B
SAA ProShares Ultra SmallCap6.. 0.42 % 0.95 %

N/A

USD 0.04B
IJR iShares Core S&P Small-Ca.. 0.00 % 0.07 %

N/A

USD 87.73B
IJT iShares S&P Small-Cap 600.. 0.00 % 0.25 %

N/A

USD 6.50B
SPSM SPDR® Portfolio S&P 600 .. 0.00 % 0.06 %

N/A

USD 13.08B
SLYG SPDR® S&P 600 Small Cap .. 0.00 % 0.15 %

N/A

N/A
VIOO Vanguard S&P Small-Cap 60.. 0.00 % 0.15 %

N/A

N/A
ZSML:CA BMO S&P US Small Cap Inde.. 0.00 % 0.00 %

N/A

N/A
BBSC JPMorgan BetaBuilders U.S.. 0.00 % 0.00 %

N/A

USD 0.54B
ZSML-F:CA BMO S&P US Small Cap Inde.. 0.00 % 0.00 %

N/A

CAD 5.46M
ZSML-U:CA BMO S&P US Small Cap Inde.. 0.00 % 0.00 %

N/A

N/A
QVMS Invesco Exchange-Traded F.. 0.00 % 0.00 %

N/A

USD 0.21B
WELP:LSE HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 90.16% 94% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 90.16% 94% A 97% N/A
Trailing 12 Months  
Capital Gain 90.16% 94% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 90.16% 94% A 97% N/A
Trailing 5 Years  
Capital Gain 179.00% 96% N/A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 179.00% 96% N/A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 35.70% 87% B+ 90% A-
Dividend Return 35.70% 87% B+ 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 55.17% 29% F 17% F
Risk Adjusted Return 64.70% 97% N/A 78% C+
Market Capitalization 1.10B 67% D+ 84% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 42.30 35% 6%
Price/Book Ratio 12.44 12% 8%
Price / Cash Flow Ratio -144.03 100% 99%
Price/Free Cash Flow Ratio -57.89 100% 99%
Management Effectiveness  
Return on Equity -26.10% 31% 14%
Return on Invested Capital -16.66% 30% 11%
Return on Assets -7.74% 44% 11%
Debt to Equity Ratio 61.24% 33% 55%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector